FDA approves Pfizer’s abuse-deterrent opioid painkiller

pharmafile | August 22, 2016 | News story | Sales and Marketing FDA, Pfizer, abuse deterrent, abuse-deterrent, approval, opioid, troxyca 

Pfizer has announced that the US FDA has approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Troxyca becomes the first and only oxycodone with oral-abuse deterrent features described in the labelling. The medicine has properties that are expected to reduce abuse when crushed and administered by the oral and intranasal routes.

The extended-release capsules contain pellets that consist of opioid agonist, oxycodone hydrochloride, which surround opioid antagonist, naltrexone hydrochloride. Pfizer indicates that studies have shown that when the pellets are crushed, the sequestered naltrexone is released and is available to counteract the effects of oxycodone.

Advertisement

Rory O’Connor, chief medical officer of internal medicine, at Pfizer, says: “Public health authorities and regulators have encouraged the development of treatments that are more difficult to abuse, yet offer pain relief to appropriate patients when used as indicated. The development of this medication with abuse-deterrent properties is another example of our ongoing commitment to advancing science and the treatment of patients with pain condition.”

Sean Murray

Related Content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

Johnson & Johnson submits robotic surgical system for De Novo classification

Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …

The Gateway to Local Adoption Series

Latest content